Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
32 hedge funds and large institutions have $29.4M invested in Achilles Therapeutics in 2024 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
60% more funds holding
Funds holding: 20 → 32 (+12)
52% more capital invested
Capital invested by funds: $19.4M → $29.4M (+$10M)
4.24% more ownership
Funds ownership: 53.41% → 57.65% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.56M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$1.5M |
| 3 |
SC
Stempoint Capital
New York
|
+$1.49M |
| 4 |
Renaissance Technologies
New York
|
+$547K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$454K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.62M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.26M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$964K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$23.2K |
| 5 |
VF
Virtu Financial
New York
|
-$20.1K |
ACHL Hedge Fund Activity: Q1 2024 in Review
32 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2024, worth a combined $29.4M — up 52% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ACHL positions and 1 closed out — a net gain of 12 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.56M. The largest seller was Artal Group, cutting an estimated $1.62M.
- 32 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2024, up from 20 in Q4 2023.
- Funds reported $29.4M of Achilles Therapeutics stock for Q1 2024, up 52% quarter-over-quarter.
- 13 funds opened new Achilles Therapeutics positions in Q1 2024 and 1 closed out, a net change of +12 holders.
- The largest Achilles Therapeutics buyer in Q1 2024 was Ikarian Capital, an estimated $1.56M added.
- The largest Achilles Therapeutics seller in Q1 2024 was Artal Group, an estimated $1.62M sold.
Based on aggregated 13F filings for Q1 2024.